Table 4.
Relationship Between ANGPTL4 in HDLs and Other Components in HDLs
| Nondiabetic Participants | T2DM Patients | |||
|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |
| R | Estimate (95% CI) | r | Estimate (95% CI) | |
| Number | 201 | 201 | 185 | 185 |
| Cholesterol, mmol/L | −0.135 | −0.37 (−0.71, −0.03)* | −0.169* | −0.72 (−1.40, −0.04)* |
| apoA‐I, μg/mL | 0.156* | 0.06 (0.01, 0.12) | −0.083 | −0.06 (−0.19, 0.07) |
| Serum amyloid A, μg/L | −0.169* | −9.41 (−17.32, −1.50)* | −0.039 | 3.64 (−16.49, 23.77) |
| Phospholipid, mg/dL | −0.137 | −0.93 (−1.00, −0.87)* | 0.041 | 1.03 (0.96, 1.10) |
| Triglyceride, mg/dL | 0.130 | 1.04 (0.99, 1.10) | 0.113 | 1.06 (0.99, 1.12) |
All associations were adjusted for age, sex, body mass index, mean arterial pressure, and lipid‐lowering drugs. Estimates given with 95% CI express the difference in HDL components associated with 1 doubling increase of ANGPTL4 in HDLs. ANGPTL4 indicates angiopoietin‐like protein 4; apoA‐I, apolipoprotein A‐I; HDL, high‐density lipoprotein; T2DM, type 2 diabetes mellitus.
Significance: *P<0.05.